No worries if you cannot answer for disclosure reasons, but I am curious where you got the estimations from? Be looking at around $1 million revenues in Oz, that pale in comparison to the some $30 million from the US and $15 million in EU on that basis.
Throw in CelGro Nerve revenues and initial and milestone payments from a J&J partnership and revenues could go exponential pretty quickly, as will the share price of course....these bio-techs prospects are like call options from an investment perspective, one day apt to take off.
No worries if you cannot answer for disclosure reasons, but I am...
-
- There are more pages in this discussion • 98 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
66.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $139.0M | |||
| Open | High | Low | Value | Volume |
| 66.5¢ | 66.5¢ | 64.5¢ | $276.6K | 421.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 25500 | 65.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.0¢ | 9999 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |